核苷酸切除修复交叉互补基因1与卵巢癌顺铂耐药的关系

目的 探讨核苷酸切除修复交叉互补基因1(ERCC1)与卵巢癌顺铂(DDP)耐药的关系.方法 分别应用免疫组化、逆转录聚合酶链反应(RT-PCR)和Western blot检测58例卵巢癌组织和ES-2、SKOV3、COC1、COC1/DDP 4株卵巢癌细胞系中ERCC1基因的表达,分析该基因与DDP化疗耐药的关系,并观察应用RNA干扰技术干扰了ERCC1基因后卵巢癌细胞对DDP敏感性的变化.结果 58例卵巢癌组织中,ERCC1表达阳性者22例,阳性率为37.9%.ERCC1的表达与DDP化疗敏感性有关(P＜0.05),DDP耐药者ERCC1表达的阳性率(57.89%)显著高于敏感者(28.21%,P=0.029).ES-2、SKOV3、COC1、COC1/DDP 4株卵巢癌细胞ERCC1基因的表达与DDP IC50正相关(r=0.932,P＜0.05).RNA干扰ERCC1基因后,ES-2、SKOV3、COC1/DDP细胞对DDP的敏感性分别增加了53.88、5.07、3.75倍.结论 ERCC1基因与卵巢癌DDP耐药有关,RNA干扰ERCC1基因可增强卵巢癌细胞对DDP的敏感性.     

核苷酸切除修复基因XPA反义RNA增强肺癌细胞对顺铂的敏感性

背景与目的：目前认为,肿瘤细胞自身核苷酸切除修复(nucleotide excision repair,NER)能力增强是肿瘤细胞产生耐药性最重要的机制之一。着色性干皮病A(xeroderma pigmentosun groupA,XPA)基因在核苷酸切除修复早期发挥核心作用。本研究拟探讨XPA基因表达与肺癌细胞株对顺铂敏感性的关系。方法：将XPA的反义RNA稳定转染人肺癌细胞株A549．用有限稀释法筛选阳性细胞克隆。分别用Northern blot和Western blot法检测阳性细胞克隆XPA mRNA和蛋白水平;MTT法检测肿瘤细胞对顺铂敏感性;宿主细胞再活化反应(host cell reactivation,HCR)检测肿瘤细胞DNA损伤修复能力。结果：筛选得到6个阳性克隆AS1～AS6,其中AS3～AS6细胞克隆的XPAmRNA和蛋白水平均明显降低。剂量依赖实验表明,顺铂对A549细胞与AS1～AS6细胞克隆的半数抑制浓度(IC50)分别为8．1、7．6、4．7、3．2、1．9、2．8、4．1~g／ml。统计学分析表明．与A549细胞相比,AS3～AS6细胞对顺铂的敏感性明显增强(F=9．75、9．14、7．39、8．91,P=0．005、0．006、0．012、0．006),而且XPA mRNA表达水平与细胞IC50值呈显著相关(r=0．927,P=0．003)。处理24、48、72h后,AS3～AS6细胞对顺铂的敏感性同样显著增强。HCR实验结果表明,AS3～AS6细胞的NER能力显著减弱,而且XPA mRNA表达水平与细胞NER能力呈显著相关(r=0．854、0．696、0．858;p=0．014、0．082、0．013)。结论：XPA反义RNA转染可明显降低肺癌细胞XPAmRNA水平,减弱细胞NER能力,继而使肺癌细胞对顺铂的敏感性增强。     

晚期非小细胞肺癌患者XPG基因及MDR1基因单核苷酸多态性与铂类化疗疗效的相关性

目的探讨DNA修复基因XPG以及多药耐药基因MDR1的单核苷酸多态性与晚期非小细胞肺癌患者对铂类为主的化疗方案敏感性的关系。方法经病理确诊的晚期NSCLC患者101例,采用DDP为主的化疗方案,化疗2～3个周期后进行临床疗效评价。以PCR-RLFP方法进行XPG、MDR-1的基因型分析,比较不同基因型对化疗敏感性的影响。结果携带MDR1-3435等位基因C/C的患者的化疗有效率为57.8%,显著高于至少携带1个T等位基因的26.8%（OR=0.272,95%CI=0.117～0.635,P（0.05））;携带MDR1-2677至少1个T等位基因的患者的化疗有效率12.8%要显著低于其他基因型患者的58.1%（OR=17.999,95%CI=4.938～65.599,P（0.01）;而XPG各基因型与化疗敏感性的关系没有显著性的差异。结论MDR1基因多态性与NSCLC患者对铂类药物的化疗敏感性相关,基因XPG的多态性是否与铂类药物化疗的敏感性是否具有相关性尚需进一步的研究。     

碱基切除修复基因多态性与晚期非小细胞肺癌铂类药物化疗敏感性

目的:探讨DNA碱基切除修复通路中XRCC1 Arg399Gln和ADPRT Val762Ala基因多态性与晚期非小细胞肺癌(NSCLC)铂类药物化疗敏感性的关联,并与先前报道的XRCC1 T-77C、Argl94Trp联合分析其预测作用.方法:收集接受铂类药物为基础化疗的晚期NSCLC患者107例,用PCR-RFLP法检测基因型,分析各基因型与铂类药物化疗有效率的关联,并以非条件Logistic回归模型对患者年龄、性别、病理类型、临床分期和治疗方案进行校正.结果:对XRCC1 Arg399Gln多态性进行单因素分析时,发现携带至少1个Gln等位基因的患者的化疗有效率是携带Arg/Arg基因型者的0.42倍(95%CI:0.19-0.93),差异具有统计学意义;经多因素校正后发现携带至少1个Gln等位基因的患者的化疗有效率是携带Arg/Arg基因型者的0.52倍(95%CI:0.22-1.26),但差异不再具有统计学意义.对ADPRT Val762Ala多态性进行多因素分析时,发现携带至少1个Ala等位基因的患者的化疗有效率是携带Val/Val基因型者的1.57倍(95%CI:0.67-3.66).联合分析各患者4个多态性位点的铂类药物敏感基因型的总数目与铂类药物化疗有效率的关联,并经多因素分析校正后,发现携带3-4个铂类药物敏感基因型的患者的化疗有效率是具有0-2个铂类药物敏感基因型者的4.15倍(95%CI:1.54-11.19),差异具有统计学意义.结论:XRCC1 Arg399Gln多态性与铂类药物化疗敏感性的关系需进一步确认,似乎携带野生型Arg/Arg者对铂类药物化疗更敏感;但未能发现ADPRTVal762Ala多态性与铂类药物化疗敏感性存在明显关联;4个多态性位点联合分析的预测效能高于单个位点.     

核苷酸切除修复与铂类耐药研究进展

目前肿瘤化疗仍以肿瘤发生部位和病理类型为基础选择药物,由于肿瘤本身以及个体之间存在异质性,相同部位和相同病理类型的肿瘤对化疗敏感性存在差异。长期以来,人们追求根据肿瘤自身药物敏感性开展个体化治疗。近年来,药物敏感相关基因检测获得快速发展,使个体化化疗成为可能。在相关基因与化疗药物研究领域中,核苷酸切除修复基因与铂类药物研究是最受瞩目的内容之一。1铂类药物耐药机制铂类药物(顺铂、卡铂、草酸铂)是临床上最常用的一类化疗药物。铂类药物进入肿瘤细胞后与DNA结合,形成Pt-DNA加合物,导致DNA的链间或链内交链,引起DNA复制障碍,从而抑制肿瘤细胞分裂。铂类药物的耐药机制主要有减少药物摄取积聚、通过共扼结合去除药物毒性、提高对铂类药物诱导产生的DNA加合物的耐受性及提高DNA修复能力等。研究证实,临床缓解率与循环中Pt-DNA加合物的水平相关,如果肿瘤细胞DNA修复能力减低,就会导致Pt-DNA加合物清除减少,使患者对铂类药物的疗效提高,反之疗效则差。因此,DNA修复能力是影响铂类药物疗效的主要原因。DNA切除修复途径主要有碱基切除修复(base-exc ision repair,BER)、DNA双链断裂修复(DN...     

核苷酸切除修复基因多态性和铂类药物耐药性关系研究进展

铂类药物广泛用于实体肿瘤的化疗,其作用机制与肿瘤细胞DNA的损伤有关,然而,机体的DNA修复机制可以将这些损伤修复.核苷酸切除修复是DNA修复中的一种,目前认为核苷酸切除修复与铂类药物的耐药相关.本文就核苷酸切除修复基因多态性和铂类药物耐药性关系研究进展作一综述.     

碱基切除修复基因多态性与晚期非小细胞肺癌铂类药物化疗敏感性

目的：探讨DNA碱基切除修复通路中XRCC1 Arg399Gln和ADPRT Val762Ala基因多态性与晚期非小细胞肺癌（NSCLC）铂类药物化疗敏感性的关联,并与先前报道的XRCC1 T-77C、Argl94Trp联合分析其预测作用。方法：收集接受铂类药物为基础化疗的晚期NSCLC患者107例,用PCR—RFLP法检测基因型,分析各基因型与铂类药物化疗有效率的关联,并以非条件Logistic回归模型对患者年龄、性别、病理类型、临床分期和治疗方案进行校正。结果：对XRCC1 Arg399Gln多态性进行单因素分析时,发现携带至少1个Gln等位基因的患者的化疗有效率是携带Arg／Arg基因型者的0．42倍（95％CI：0．19—0．93）,差异具有统计学意义;经多因素校正后发现携带至少1个Gln等位基因的患者的化疗有效率是携带Arg／Arg基因型者的0．52倍（95％CI：0．22—1．26）,但差异不再具有统计学意义。对ADPRT Val762Ala多态性进行多因素分析时,发现携带至少1个Ala等位基因的患者的化疗有效率是携带Val／Val基因型者的1．57倍（95％CI：0．67—3．66）。联合分析各患者4个多态性位点的铂类药物敏感基因型的总数目与铂类药物化疗有效率的关联,并经多因素分析校正后,发现携带3—4个铂类药物敏感基因型的患者的化疗有效率是具有0—2个铂类药物敏感基因型者的4．15倍（95％CI：1．54—11．19）,差异具有统计学意义。结论：XRCC1 Arg399Gln多态性与铂类药物化疗敏感性的关系需进一步确认,似乎携带野生型Arg／Arg者对铂类药物化疗更敏感;但未能发现ADPRT Val762Ala多态性与锥苑矧别眇德魄牲存在明显关联;4个多态性位点联合分析的预测效能高于单个位点。     

核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系

背景与目的:肿瘤细胞对铂类药物的化疗敏感性与个体的DNA损伤修复能力关系密切,本研究探讨核苷酸切除修复系统(nucleotideexcisionrepair,NER)的重要成员XPC、XPD和ERCC1基因的遗传多态与晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)患者对铂类药物敏感性的关系。方法:对接受含铂类药物化疗的200例晚期NSCLC患者进行临床疗效评价。以聚合酶链-扩增片段长度多态性(PCR-AFLP)和限制性片段长度多态性(RFLP)的方法检测XPC-PAT、XPDLys751Gln(rs1052559)和ERCC1C8092A(rs1052559)多态的基因型,比较不同基因型与化疗敏感性的关系。结果:结合疗效情况,XPC-PAT遗传多态各基因型在化疗有效组(CR PR)和无效组(SD PD)中的分布频率差异有显著性(!2检验,P=0.023),携带XPCLL基因型个体的化疗敏感性是XPCSS基因型携带者的3.04倍(95%CI为1.25～7.41,P=0.015)。没有发现XPDLys751Gln和ERCC1C8092A多态与化疗敏感性的相关性。但联合分析后发现,核苷酸切除修复系统的这三个遗传多态在晚期NSCLC患者对铂类药物敏感性中存在一定的联合作用(趋势检验,P=0.021)。结论:核苷酸切除修复系统中XPC-PAT、XPDLys751Gln和ERCC1C8092A遗传多态可能与NSCLC患者对铂类药物敏感性相关。     

RRM1基因多态性与非小细胞肺癌患者血清铂类化疗敏感的相关性分析

目的:观察RRM1亚基基因多态性对预测非小细胞肺癌(non-small cell lung cancer,NSCLC)患者以铂类为基础的化疗方案的敏感性和化疗毒性的临床价值.方法:用PCR-RFLP技术检测214例NSCLC患者RRM1启动子基因型.所有患者均经以铂类为基础的化疗方案治疗.结果:214例NSCLC病例中,RR37C/C、C/A和A/A基因型分别为11 6例(54.46%)、87例(40.85%)和10例(4.69%),化疗有效率分别为44.83%(52/116)、45.98%(40/87)和30.00%(3/10),差异无统计学意义(P=0.629),调整OR值为0.68(95%CI:0.16～2.85);RR524 C/C、C/T和T/T基因型分别为25例(11.68%)、89例(41.59%)和100例(46.73%),化疗有效率分别为24.00%(6/25)、51.69%(46/87)和43.00%(43/100),差异有统计学意义(P=0.046),C/T+T/T基因组的有效率显著高于C/C基因组,P=0.008.携带RR524T等位基因型者的化疗敏感性是RR524C/C基因型患者的2.7倍,调整OR=2.70(95%CI为0.98～7.41).化疗后总有效率(完全缓解+部分缓解)为44.4%.RR37A/A基因型患者化疗相关的血转氨酶升高显著高于C/C、C/A基因型者,P=0.02.结论:RRM1基因RR524基因型多态性可影响以铂类为基础的化疗方案治疗肺癌的敏感性,RRM1基因检测对指导NSCLC的化疗、预测疗效具有较高的临床价值.     

INSR基因多态性与卵巢上皮癌化疗敏感性的相关性研究

目的 探讨INSR基因多态性与卵巢上皮癌(EOC)铂类化疗敏感性的关系.方法 收集339例接受手术及术后化疗的EOC患者资料,INSR基因标签的单核苷酸多态从HapMap基因组数据结合现有文献中筛选出来,胰岛素受体基因型和等位基因频率分布由ABI3100-Avant测序.比较EOC化疗敏感与不敏感患者中INSR基因多态性的分布差异及可能影响EOC化疗敏感性的基因型.结果 与rs2252673 GC+CC基因型相比,rs2252673 GG基因型携带者的铂类药物化疗敏感性更低;与rs3745546 GG+GC基因型相比,rs3745546 CC基因型携带者的铂类药物化疗敏感性更低.Logistic分析显示rs2252673和rs3745546基因多态性是影响EOC患者化疗敏感性的主要因素(P﹤0.05).结论 INSR rs2252673和rs3745546的基因多态性可能与EOC患者铂类化疗敏感性有关.     

核苷酸切除修复系统基因多态性与淋巴造血系统肿瘤药物治疗反应的研究进展

核苷酸切除修复途径是细胞内最主要、最灵活的DNA修复方式.单核苷酸多态性(single nucleotide polymorphisms,SNPs)是人类第三代分子遗传标志物,反映了个体表型、疾病易感性以及对药物、环境等影响因素反应的差异.淋巴造血系统肿瘤是一种多基因遗传疾病,涉及到多个遗传易感基因的相互作用.全文就NER基因多态性与淋巴造血系统肿瘤药物反应性密切关联的相关基因进展作一综述.     

Impact of Polymorphism in Base Excision Repair and Nucleotide Excision Repair Genes and Risk of Cervical Cancer: A Case-Control Study

Background: Last few years, several studies all over the world revealed the association of DNA repair genes with risk of developing different type of cancers, but were ambiguous to support the evidences in case of cervical cancer risk. These differences in earlier studies directed us to study the association of polymorphisms of BER genes (XRCC1, hOGG1, XPC) and NER genes (XPC, XPD) with cervical cancer susceptibility in the women of rural population of Maharashtra. Materials and Methods: The genetic polymorphism in BER and NER pathway genes was studied by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using DNA isolated from intravenous blood samples of patients and normal controls. The study included 400 clinically confirmed cervical cancer patients and 400 healthy women from a tertiary care hospital (Krishna Hospital and Medical Research Centre) of south-western Maharashtra. The association of polymorphisms was confirmed by Odds ratio (OR) with 95% confidence interval. Results: The single nucleotide polymorphism (SNP) of BER genes including XRCC1, hOGG1 and APE1 were analyzed and the results were noted that 27466AA (OR=4.88; 95% CI: 3.61- 6.60; p<0.0001) and 28152AA (OR=2.89; 95% CI: 1.57- 5.31; p=0.0005) genotypes of XRCC1 (rs25489, rs25487) were significantly associated with cervical cancer risk. The 1245GG genotype of hOGG1 (rs1052133) (OR=45.30; 95% CI: 3.76- 7.46; p=0.001) also showed significant correlation, whereas 2197GG genotype of APE1 (rs1130409) gene showed negative association with cervical carcinogenesis (OR=0.59; 95% CI: 0.35- 0.97; p=0.005). Similarly when we studied SNPs of NER genes including XPC and XPD genes, 21151TT genotype of XPC (rs 2228000) was positively associated with cervical cancer development and 23591AA genotype of XPD (rs1799793) showed negative association (OR=0.34; 95% CI: 0.17- 0.64; p=0.001). Conclusion: The findings from this study supported that rs25489, rs25487SNPs of XRCC1, rs1052133 of hOGG1 and rs2228000 of XPC may increase cervical cancer risk, whereas rs1130409 SNP of APE1 and rs1799793 SNP of XPD gene lower the risk of cervical cancer in the studied population.     

Nucleotide Excision Repair Capacity and XPC and XPD Gene Polymorphism Modulate Colorectal Cancer Risk

Background

Colorectal cancer (CRC) is leading malignant tumors to occur mainly in industrialized countries, where it exhibits one of the highest mortality rates. Up to 80% of all CRCs characterize a chromosomal instability (CIN) phenotype. The main challenge faced by scientist is to reveal the mechanism of CIN development. An often proposed model is defects in DNA repair in terms of efficiency and genetic variations that modulate the response to stimuli from the environment. The objectives of this research were to determine whether nucleotide excision repair (NER) might affect CRC risk.

切除修复交叉互补基因1（ERCC1）在卵巢癌中的研究进展

切除修复交叉互补基因1（ERCC1）是苷酸切除修复途径的关键基因。它参与了铂类药物耐药的形成．影响了正常组织的耐受性以及患者的预后。全文阐述ERCC1的生物学特性．分析ERCC1与铂类药物耐药性的关系及在卵巢癌中的研究进展。     

Analysis of DNA Repair Genes Polymorphisms in Breast Cancer

Genetic polymorphisms in the DNA repair genes may be associated with increased cancer risk. The purpose of this study was to evaluate the association of the DNA repair genes polymorphisms with the risk of breast cancer development. The study included 200 breast cancer patients and 200 healthy controls. The following polymorphisms were studied: C/G (Ser326Cys, rs1052133) of the hOGG1, A/C (IVS5 + 33, rs3212961) of the ERCC1, A/C (Lys939Gln, rs2228001) of the XPC, C/T (Thr241Met, rs861539) of the XRCC3, G/T (Leu787Leu, rs1800392) of the WRN and G/T (Ser307Ser, rs1056503) of the XRCC4 gene. Presented study showed statistically significant increase in the breast cancer development risk of the G/G hOGG1 genotype (OR 8.13; 95 % CI, 4.37–15.14; p < 0.001) and for the G hOGG1 allele (OR 5.11; 95 % CI, 3.69–7.06; p < 0.001), as well as for the C/C ERCC1 genotype (OR 10.61; 95 % CI, 5.72–19.69; p < 0.001) and the C ERCC1 allele (OR 4.66; 95 % CI, 3.43–6.34; p < 0.001) in patients with breast cancer in comparison with healthy control group. We also observed positive association of the C/C XPC genotype (OR 3.80; 95 % CI, 2.27–6.38; p < 0.001) as well as the C XPC allele occurrence with an increased breast cancer development risk (OR 2.65; 95 % CI, 1.98–3.55; p < 0.001). Furthermore, we found an association of the G/T WRN gene polymorphism with increased risk of carcinoma. The hOGG1, ERCC1, XPC and WRN genes polymorphisms may be related to development of breast cancer.     

Efficacy and Toxicity of Gemcitabine and Pegylated Liposomal Doxorubicin in Recurrent Platinum - Resistant/Refractory Epithelial Ovarian Cancer

Background: Treatment of patients with platinum resistant/refractory ovarian cancer is a significant problem.In this study, we evaluated the efficacy and tolerability of the combination of gemcitabine and pegylated liposomaldoxorubicin (PLD) in patients with platinum resistant/refractory ovarian cancer. Patients and Methods: Weretrospectively evaluated the activity and toxicity of gemcitabine and PLD combination in 35 patients withrecurrent platinum resistant/refractory ovarian cancer who had been treated and followed up in 7 centers inTurkey between December 2005 and June 2008. The patients received gemcitabine 1.000 mg/m2 on day 1 and 8,and PLD 25 mg/m2 on day 1 every 28 days. Results: A total of 187 cycles (median, 6 cycles) were delivered. Anobjective response rate of 28,6 % (1 complete, 9 par tial response) was achieved. Additionally, 16 patients (45.7%) had disease stabilization. The median time-to-progression was 6 months (95 % confidence interval, 4-8) andthe median overall survival was 17 months (95 % confidence interval, 12-22). Grade 3-4 hematologic toxicitieswere as follows: leucopenia (14.3%), neutropenia (8.6%), and anemia (2.9%). One febrile neutropenic episode(2.9%) was observed. Non-hematologic toxicity was well tolerated and easily managed and no grade 3-4palmoplantar erytrodysestesia (PPE) was observed. Conclusion: The combination of gemcitabine and PLD isan effective and tolerable treatment option, with 74.3 % disease control rate for patients with platinum resistant/refractory ovarian cancer.     

高表达bcl-2卵巢癌细胞系参与药物抵抗和细胞凋亡作用的研究 *

目的：探讨化疗的敏感性与细胞凋亡的关系,观察细胞凋亡抑制分子ｂｃｌ－２在卵巢癌化疗抵抗中的作用。方法：构建了逆转录病毒ｂｃｌ－２表达载体ｐＬＸＳＮ／ｂｃｌ－２,应用ｌｉｐｏｆａｃｔｉｎ法建立转染ｂｃｌ－２基因和转染空载体ｐＬＸＳＮ的卵巢癌细胞系。ＭＴＴ法观察细胞系抵抗药物的细胞毒作用。ＦＡＣＳ和ＤＮＡ琼脂糖凝胶电泳观察ｂｃｌ－２高表达细胞系在阿霉素诱导细胞凋亡中的变化。结果：转染 ｂｃｌ－２的卵巢癌细胞系ＯＣ３／ｂｃｌ－２稳定表达ｂｃｌ－２分子并抵抗药物介导的细胞毒作用,明显提高细胞的存活率,与此同时也抑制细胞凋亡的发生。结论：化疗的敏感性与细胞凋亡的调节密切相关,凋亡抑制基因ｂｃｌ－２在肿瘤耐药中起重要作用。     

Polymorphisms of DNA Repair Genes in Endometrial Cancer

Endometrial cancer belongs to the commonest malignancy in females. Its development may be associated with the high exposure of endometrium to exo- and endogenous estrogens. Estrogens produce DNA bulky adducts and oxidative base damages which are removed in nucleotide excision repair (NER) and base excision repair (BER) pathways. The reaction of endometrial cells to DNA damage may be crucial for their susceptibility to cancer transformation. This reaction is executed mainly by DNA repair, which can be modulated by the variability in the genes encoding DNA repair proteins. In this report we genotyped 4 polymorphisms of 3 DNA repair genes in 94 endometrial cancer patients and 114 age-matched cancer-free women using RFLP-PCR. The following polymorphisms were studied: p.Arg194Trp, p.Arg399Gln of the XRCC1 gene, p.Ser326Cys of the hOGG1 gene and p.Lys751Gln of the ERCC2 gene. We found an association between the ERCC2 751Gln variant and endometrial cancer occurrence (OR 3.95; 95?% CI 1.88-8.31). Gene-gene interaction between the ERCC2 751Gln and XRCC1 194Trp variants also increased the risk of endometrial cancer (OR 4.41; 95?% CI 2.01-9.67). The risk in the carriers of the ERCC2 751Gln variant was increased by a positive cancer history in first degree relatives (OR 4.97; 95?% CI 1.98-12.48). The risk of endometrial cancer was not alter by polymorphism p.Ser326Cys of the hOGG1 gene. The 751 Lys/Gln polymorphism of the ERCC2 gene may be linked with endometrial cancer occurrence and its effect can be potentiated by variants of the XRCC1 gene or first degree relatives positive cancer history.     

紫杉醇联合铂类疗效与Stathmin基因表达在卵巢癌中的相关性

目的 探讨紫杉醇联合铂类在卵巢癌患者中的临床疗效及其与stathmin基因表达相关性.方法 选取120例卵巢癌患者资料进行分析,将患者根据随机数字方法分为2组,每组60例.对照组采用伊立替康联合顺铂方案治疗,研究组采用紫杉醇联合铂类方案治疗,患者治疗前后利用免疫组化和逆转录聚合酶链反应(RT-PCR)方法检测stath-min基因表达,分析2组患者临床疗效及stathmin基因表达情况.结果 研究组治疗总有效率为68.3%,显著高于对照组的57.1%(P<0.05).2组患者治疗前stathmin基因表达水平差异不具有统计学意义(P>0.05);研究组治疗后stath-min基因表达水平,显著低于对照组(P<0.05).结论 卵巢癌患者采用紫杉醇联合铂类方案治疗效果理想,且stathmin基因表达越低,治疗预后越好,不良反应发生率低,值得推广应用.